Wedbush resumed coverage on MoonLake Immunotherapeutics with a new price target

11/5/24 6:22:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Wedbush resumed coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $73.00 from $92.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MLTX

Date	Price Target	Rating	Analyst
5/19/2025	$61.00	Peer Perform → Outperform	Wolfe Research
3/18/2025	$67.00	Outperform	RBC Capital Mkts
1/17/2025	$62.00 → $82.00	Neutral → Buy	Goldman
11/5/2024	$92.00 → $73.00	Outperform	Wedbush
8/26/2024		Outperform → Peer Perform	Wolfe Research
6/25/2024	$104.00	Outperform	Oppenheimer
4/2/2024	$62.00	Neutral	Goldman
2/15/2024	$77.00	Outperform	Wolfe Research